S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.40 (-1.32%)
AAPL   163.91 (+2.29%)
MSFT   331.43 (-1.54%)
FB   327.70 (-3.06%)
GOOGL   2,853.08 (-1.98%)
AMZN   3,514.53 (-1.32%)
TSLA   1,135.88 (-0.10%)
NVDA   323.96 (-2.94%)
BABA   127.48 (-3.14%)
NIO   39.14 (-3.26%)
CGC   10.48 (-5.24%)
AMD   157.48 (-2.74%)
GE   95.40 (-3.05%)
MU   85.01 (-1.31%)
T   22.68 (-5.06%)
F   19.24 (-2.19%)
DIS   144.18 (-2.46%)
ACB   6.24 (-3.11%)
AMC   34.13 (-7.36%)
PFE   54.15 (+3.34%)
BA   195.50 (-1.51%)
S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.40 (-1.32%)
AAPL   163.91 (+2.29%)
MSFT   331.43 (-1.54%)
FB   327.70 (-3.06%)
GOOGL   2,853.08 (-1.98%)
AMZN   3,514.53 (-1.32%)
TSLA   1,135.88 (-0.10%)
NVDA   323.96 (-2.94%)
BABA   127.48 (-3.14%)
NIO   39.14 (-3.26%)
CGC   10.48 (-5.24%)
AMD   157.48 (-2.74%)
GE   95.40 (-3.05%)
MU   85.01 (-1.31%)
T   22.68 (-5.06%)
F   19.24 (-2.19%)
DIS   144.18 (-2.46%)
ACB   6.24 (-3.11%)
AMC   34.13 (-7.36%)
PFE   54.15 (+3.34%)
BA   195.50 (-1.51%)
S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.40 (-1.32%)
AAPL   163.91 (+2.29%)
MSFT   331.43 (-1.54%)
FB   327.70 (-3.06%)
GOOGL   2,853.08 (-1.98%)
AMZN   3,514.53 (-1.32%)
TSLA   1,135.88 (-0.10%)
NVDA   323.96 (-2.94%)
BABA   127.48 (-3.14%)
NIO   39.14 (-3.26%)
CGC   10.48 (-5.24%)
AMD   157.48 (-2.74%)
GE   95.40 (-3.05%)
MU   85.01 (-1.31%)
T   22.68 (-5.06%)
F   19.24 (-2.19%)
DIS   144.18 (-2.46%)
ACB   6.24 (-3.11%)
AMC   34.13 (-7.36%)
PFE   54.15 (+3.34%)
BA   195.50 (-1.51%)
S&P 500   4,596.29 (-1.27%)
DOW   34,662.39 (-1.35%)
QQQ   394.40 (-1.32%)
AAPL   163.91 (+2.29%)
MSFT   331.43 (-1.54%)
FB   327.70 (-3.06%)
GOOGL   2,853.08 (-1.98%)
AMZN   3,514.53 (-1.32%)
TSLA   1,135.88 (-0.10%)
NVDA   323.96 (-2.94%)
BABA   127.48 (-3.14%)
NIO   39.14 (-3.26%)
CGC   10.48 (-5.24%)
AMD   157.48 (-2.74%)
GE   95.40 (-3.05%)
MU   85.01 (-1.31%)
T   22.68 (-5.06%)
F   19.24 (-2.19%)
DIS   144.18 (-2.46%)
ACB   6.24 (-3.11%)
AMC   34.13 (-7.36%)
PFE   54.15 (+3.34%)
BA   195.50 (-1.51%)
NASDAQ:PATH

UiPath Stock Forecast, Price & News

$48.02
-1.47 (-2.97%)
(As of 11/30/2021 01:51 PM ET)
Add
Compare
Today's Range
$47.66
$50.16
50-Day Range
$47.87
$57.51
52-Week Range
$46.66
$90.00
Volume
122,441 shs
Average Volume
4.12 million shs
Market Capitalization
$24.66 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive PATH News and Ratings via Email

Sign-up to receive the latest news and ratings for UiPath and its competitors with MarketBeat's FREE daily newsletter.


UiPath logo

About UiPath

UiPath Inc. provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. It develops UiPath Studio, a platform designed for RPA developers looking to build complex process automations with built-in governance capabilities, such as robust debugging tools, application programming interface automation, wizards to automate desktop or web applications, leverage custom code, and to integrate machine learning models into production workflows. The company also offers UiPath Robots, which emulates human behavior to execute the processes built in UiPath Studio; and UiPath Orchestrator that tracks and logs robot activity, along with what people do in tandem to maintain strict compliance and governance through dashboards and visualization tools. In addition, it provides maintenance and support for its software, as well as professional services, such as training and implementation services to facilitate the adoption of its platform. UiPath Inc. was founded in 2005 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Prepackaged software
Sub-Industry
N/A
Current Symbol
NASDAQ:PATH
Fax
N/A
Employees
2,863
Year Founded
2005

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
366,664,000
Market Cap
$24.66 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
9/06/2021
Today
11/30/2021
Next Earnings (Confirmed)
12/08/2021
Fiscal Year End
1/31/2022

Social Links


MarketRank

Overall MarketRank

2.26 out of 5 stars

Business Services Sector

96th out of 423 stocks

Prepackaged Software Industry

71st out of 266 stocks

Analyst Opinion: 4.2Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












UiPath (NASDAQ:PATH) Frequently Asked Questions

Is UiPath a buy right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for UiPath in the last year. There are currently 2 sell ratings, 11 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" UiPath stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PATH, but not buy additional shares or sell existing shares.
View analyst ratings for UiPath
or view top-rated stocks.

How has UiPath's stock been impacted by COVID-19 (Coronavirus)?

UiPath's stock was trading at $18.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PATH stock has increased by 166.2% and is now trading at $47.92.
View which stocks have been most impacted by COVID-19
.

When is UiPath's next earnings date?

UiPath is scheduled to release its next quarterly earnings announcement on Wednesday, December 8th 2021.
View our earnings forecast for UiPath
.

How can I listen to UiPath's earnings call?

UiPath will be holding an earnings conference call on Wednesday, December 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415.

How were UiPath's earnings last quarter?

UiPath Inc. (NASDAQ:PATH) posted its quarterly earnings results on Monday, September, 6th. The healthcare company reported $0.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.06. The healthcare company had revenue of $195.52 million for the quarter, compared to the consensus estimate of $186.72 million. The business's quarterly revenue was up 40.3% compared to the same quarter last year.
View UiPath's earnings history
.

What guidance has UiPath issued on next quarter's earnings?

UiPath updated its third quarter 2022 earnings guidance on Tuesday, October, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $207 million-$209 million, compared to the consensus revenue estimate of $206.17 million.

What price target have analysts set for PATH?

23 analysts have issued 12 month target prices for UiPath's shares. Their forecasts range from $40.00 to $86.00. On average, they expect UiPath's stock price to reach $71.00 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price.
View analysts' price targets for UiPath
or view top-rated stocks among Wall Street analysts.

Who are UiPath's key executives?

UiPath's management team includes the following people:
  • Mr. Daniel Solomon Dines, Co-Founder, CEO, & Chairman (Age 49)
  • Mr. Marius Tirca, Co-Founder & CTO
  • Mr. Ashim Gupta, Chief Financial Officer (Age 42) (LinkedIn Profile)
  • Mr. Brad C. Brubaker, Gen. Counsel, Chief Legal Officer & Sec. (Age 57) (LinkedIn Profile)
  • Mr. Robert B. Patrick, Chief Marketing Officer (Age 49)
  • Mr. Christopher Townsend, VP of Federal Sales
  • Mr. Vijay Khanna, Chief Corp. Devel. Officer
  • Ms. Bettina H. Koblick, Chief People Officer (Age 55)
  • Mr. Vargha Moayed, Chief Strategy Officer
  • Mr. Chris Klayko, Sr. VP & MD of Americas

What other stocks do shareholders of UiPath own?

When did UiPath IPO?

(PATH) raised $990 million in an initial public offering (IPO) on Wednesday, April 21st 2021. The company issued 21,300,000 shares at a price of $43.00-$50.00 per share. Morgan Stanley, JPMorgan, BofA Securities, Credit Suisse, Barclays and Wells Fargo Securities acted as the underwriters for the IPO and SMBC Nikko, BMO Capital Markets, Mizuho Securities USA, KeyBanc Capital Markets, TD Securities (USA), Truist SecuritiesCowen, Evercore Group, Macquarie Capital (USA), Nomura, RBC Capital Markets, Canaccord Genuity, D. A. Davidson & Co., Oppenheimer & Co. and Needham & Co. were co-managers.

What is UiPath's stock symbol?

UiPath trades on the NASDAQ under the ticker symbol "PATH."

When did the company's lock-up period expire?

UiPath's lock-up period expired on Monday, October 18th. UiPath had issued 23,890,777 shares in its public offering on April 21st. The total size of the offering was $1,337,883,512 based on an initial share price of $56.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are UiPath's major shareholders?

UiPath's stock is owned by a variety of institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (2.75%), Nikko Asset Management Americas Inc. (2.74%), Wellington Management Group LLP (0.79%), Allianz Asset Management GmbH (0.75%), Sands Capital Ventures LLC (0.74%) and Goldman Sachs Group Inc. (0.73%). Company insiders that own UiPath stock include Ashim Gupta, Brad Brubaker, Daniel Dines, East Fund 2013 Sca Sic Digital, Laela Sturdy, Philippe Botteri, Rich Wong, Ted Kummert and Thomas Neergaard Hansen.
View institutional ownership trends for UiPath
.

Which major investors are selling UiPath stock?

PATH stock was sold by a variety of institutional investors in the last quarter, including Dragoneer Investment Group LLC, Disruptive Technology Advisers LLC, Sands Capital Management LLC, Madrona Venture Group LLC, Sculptor Capital LP, Citigroup Inc., Allianz Asset Management GmbH, and Squarepoint Ops LLC. Company insiders that have sold UiPath company stock in the last year include Ashim Gupta, Brad Brubaker, Daniel Dines, East Fund 2013 Sca Sic Digital, Laela Sturdy, Philippe Botteri, Rich Wong, Ted Kummert, and Thomas Neergaard Hansen.
View insider buying and selling activity for UiPath
or view top insider-selling stocks.

Which major investors are buying UiPath stock?

PATH stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Sands Capital Ventures LLC, BlackRock Inc., Geode Capital Management LLC, StepStone Group LP, Eagle Asset Management Inc., and Portman Ltd.
View insider buying and selling activity for UiPath
or or view top insider-buying stocks.

How do I buy shares of UiPath?

Shares of PATH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UiPath's stock price today?

One share of PATH stock can currently be purchased for approximately $47.92.

How much money does UiPath make?

UiPath has a market capitalization of $24.61 billion.

How many employees does UiPath have?

UiPath employs 2,863 workers across the globe.

Does UiPath have any subsidiaries?

The following companies are subsidiares of UiPath: Magna View BV, Process Gold International BV, ProcessGold, StepShot, UiPath AB, UiPath Australia Pty Ltd, UiPath Canada, UiPath China - Shanghai, UiPath France SAS, UiPath GMBH, UiPath Hong Kong, UiPath KK, UiPath Limited, UiPath Ltd. (India), UiPath Ltd. (SG), UiPath Ltd. (UK), UiPath Netherlands B.V., UiPath Netherlands Holding B.V., UiPath SRL, UiPath South Korea, and UiPath Switzerland GmbH.

When was UiPath founded?

UiPath was founded in 2005.

What is UiPath's official website?

The official website for UiPath is www.nupathe.com.

Where are UiPath's headquarters?

How can I contact UiPath?

UiPath's mailing address is 7 Great Valley Pkwy Ste 300, MALVERN, PA 19355-1425, United States. The healthcare company can be reached via phone at 844-432-0455 or via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.